Notice of Knight Therapeutics’ Second Quarter 2026 Results Conference Call

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentMONTREAL, July 30, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc.

(TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its second quarter 2026 financial results on Thursday, August 6, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentDate: Thursday, August 6, 2026Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTime: 8:30 a.

m. ETArticle contentTelephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677Article contentArticle contentWebcast: www.knighttx.

com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast.Article contentTop StoriesGet the latest headlines, breaking news and columns.

There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!

A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.

We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.

Article contentReplay: An archived replay will be available for 30 days at www.knighttx.com.

________________________________________Article contentAbout Knight Therapeutics Inc.Article contentKnight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD.

For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.

com or www.sedarplus.ca.

Article contentForward-Looking StatementArticle contentThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.

Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect.

Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.

sedarplus.ca. Knight Therapeutics Inc.

disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.Article contentInvestor Contact: Knight Therapeutics Inc. Samira SakhiaArvind UtchanahPresident & Chief Executive OfficerChief Financial OfficerT: 514.

484.4483T. +514.

484.4483Email: IR@knighttx.comEmail: IR@knighttx.

comWebsite: www.knighttx.comWebsite: www.

knighttx.comArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentAdvertisement 1This advertisement has not loaded yet.Trending Bank of Canada expects economic rebound, decelerating inflation rate but risks remain News CRA denies disability credit to 'housebound' taxpayer with chemical sensitivities Personal Finance Advertisement 1Story continues belowThis advertisement has not loaded yet, but your article continues below.

Canadian lumber giant is shifting corporate support operations to Georgia Agriculture New York City offers discount to attract Canadians back Retail & Marketing Singapore's MAS Flags AI Pullback as Threat to Global Markets PMN Business Share this article in your social network Share this Story : Financial Post Copy Link Email X Reddit LinkedIn Tumblr CommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful.

Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a th